Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625705 | 0.84 | HSD17B10 (0.60) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL9795647 | 0.83 | MAP4K4 (0.57) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL8046357 | 0.81 | HSD17B10 (0.48) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL938904 | 0.80 | HSD17B10 (0.50) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL15669248 | 0.78 | HTT (0.50) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL963638 | 0.78 | KCNQ3 (0.48) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL954172 | 0.78 | MAPK1 (0.51) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL9952486 | 0.78 | KCNQ3 (0.70) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL12505604 | 0.78 | KCNQ3 (0.74) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 | |
| SCHEMBL317861 | 0.78 | HTT (0.53) | KCNQ3KCNQ2ABCB11ESR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435408-B1 | METHOD FOR PRODUCING FLUPIRTINE | CORDEN PHARMA INTERNAT GMBH (DE) | 2015-01-07 | — | — | EP | claimed |
| WO-2014068459-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2014-05-08 | — | — | WO | claimed |
| WO-2012004391-A1 | PROCESS FOR THE PREPARATION OF FLUPIRTINE MALEATE | K.H.S. PHARMA HOLDING GMBH (DE) | 2012-01-12 | — | — | WO | claimed |
| WO-2010136113-A1 | METHOD FOR PRODUCING FLUPIRTINE | CORDEN PHARMACHEM GMBH (DE) | 2010-12-02 | — | — | WO | claimed |
| CN-109053563-B | Method for preparing flupirtine hydrochloride | 四川青木制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10494404-B2 | Quinolinium conjugates of cyclosporin | UCL BUSINESS PLC (GB) | 2019-12-03 | — | — | US | disclosed |
| CN-109053563-A | A method of preparing hydrochloric acid Flupirtine | 四川青木制药有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20170349632-A1 | QUINOLIUM CONJUGATES OF CYCLOSPORIN | UCL BUSINESS PLC (GB) | 2017-12-07 | — | — | US | disclosed |
| US-9315461-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| US-9315461-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| WO-2016027089-A1 | QUINOLIUM CONJUGATES OF CYCLOSPORIN | UCL BUSINESS PLC (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-20150152057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| CN-102241626-A | Synthesis process of flupirtine maleate | BEIJING HRDX MEDICINAL TECHNOLOGIES CO LTD | 2011-11-16 | — | — | CN | disclosed |
| WO-2010136113-A1 | METHOD FOR PRODUCING FLUPIRTINE | CORDEN PHARMACHEM GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136113-A1 | METHOD FOR PRODUCING FLUPIRTINE | CORDEN PHARMACHEM GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2008110357-A1 | METHOD FOR PREPARING A FLUPIRTINE MALEATE OF A CRYSTAL MODIFICATION B | ELBION GMBH (DE) | 2008-09-18 | — | — | WO | disclosed |
| EP-0977736-B1 | PROCESS FOR PREPARING PURE FLUPIRTIN MALEATE AND ITS MODIFICATION A | AWD PHARMA GMBH & CO KG (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-0977736-A1 | PROCESS FOR PREPARING PURE FLUPIRTIN MALEATE AND ITS MODIFICATION A | ASTA Medica Aktiengesellschaft (DE) | 2000-02-09 | — | — | EP | disclosed |
| US-5959115-A | MULTISTAGE REACTION OF CATALYTIC HYDROGENATION, ACYLATION AND SALT FORMATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-09-28 | — | — | US | disclosed |
| WO-1998047872-A1 | PROCESS FOR PREPARING PURE FLUPIRTIN MALEATE AND ITS MODIFICATION A | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10494404-B2 | Quinolinium conjugates of cyclosporin | SQOR, SHMT2, CS | KCNQ3 1288/4885KCNQ2 826/4885ABCB11 222/4885 |
| US-20170349632-A1 | QUINOLIUM CONJUGATES OF CYCLOSPORIN | SHMT2, CS, SQOR | KCNQ3 3763/4885KCNQ2 3409/4885ABCB11 317/4885 |
| US-20150152057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | MAPT, TARDBP, SLC6A11 | KCNQ3 238/4885KCNQ2 206/4885ABCB11 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.